RXRX

Recursion Pharmaceuticals, Inc.

• Simply Wall St·3d ago

  Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet?

• TipRanks·05/14 20:23

  Private Markets: $2.1B for Isomorphic Labs, massive raise looming for Anthropic

• Dow Jones·05/14 17:34

  Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

• Benzinga·05/14 17:23

  Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

• TipRanks·05/14 16:25

  Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley

• TipRanks·05/13 10:45

  Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities

• Simply Wall St·05/12 07:32

  Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks

• Simply Wall St·05/10 04:37

  A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates

• PUBT·05/08 21:00

  Recursion director Christopher Gibson disposes of 60,000 shares for $134,800

• Simply Wall St·05/08 19:29

  Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap

• Seeking Alpha·05/08 17:25

  Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

• The Motley Fool·05/08 11:50

  3 Stocks Poised to Disrupt the Healthcare Market by 2030

• TipRanks·05/08 01:43

  Recursion Pharmaceuticals Balances Early Wins and Runway

• PUBT·05/07 20:53

  Recursion director Blake Borgeson disposes 30,000 shares for $105,600

• Benzinga·05/07 17:04

  Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back